Literature DB >> 12375658

Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe.

W Kurt Roth1, Marijke Weber, Sylvia Buhr, Christian Drosten, Wolfgang Weichert, Walid Sireis, Doris Hedges, Erhard Seifried.   

Abstract

BACKGROUND: HCV and HIV-1 NAT of all blood donations was initiated at our institutions in January 1997 to reduce the residual risk of transfusion-transmitted virus infections. The yield of NAT after testing more than 3.6 million donations in central Europe is reported. STUDY DESIGN AND METHODS: Automated pipetting instruments were used to pool up to 96 donor samples including those that were antibody reactive. To compensate for dilution of the individual donor samples by pooling, viruses were enriched from the pools by centrifugation at 48,000 x g. A commercial PCR (Cobas Amplicor, Roche) and an in-house PCR were applied for HCV and HIV-1 amplification, respectively.
RESULTS: Six HCV and 2 HIV-1 PCR confirmed-positive, antibody-negative donations (yield, 1 in 600,000 and 1 in 1.8 million, respectively) were identified. Thirty-nine and 11 multiple-time donors seroconverted for HCV and HIV, respectively, and look-back procedures were initiated. Archived samples from preseroconversion donations were thawed and retested by single-sample PCR and remained negative. The recipients of the blood components were traced and tested. All traced recipients were negative for HCV and HIV antibodies.
CONCLUSION: The yield of NAT in central European Red Cross blood donors was less than expected from theoretical calculations for American and German multiple-time donors. Look-back procedures for HCV and HIV indicated that no donation given before seroconversion of the donor was missed by minipool PCR. Sensitivity of minipool PCR testing after virus enrichment seems to be sufficiently high to close the diagnostic window almost completely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12375658     DOI: 10.1046/j.1537-2995.2002.00129.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  Evaluation of pooled rapid HIV antibody screening of patients admitted to a San Diego Hospital.

Authors:  Sanjay R Mehta; Vu T Nguyen; Georgina Osorio; Susan Little; Davey M Smith
Journal:  J Virol Methods       Date:  2011-04-12       Impact factor: 2.014

Review 2.  Autologous blood in obstetrics: where are we going now?

Authors:  Giancarlo Maria Liumbruno; Chiara Liumbruno; Daniela Rafanelli
Journal:  Blood Transfus       Date:  2011-10-25       Impact factor: 3.443

3.  Quarantine Plasma: Quo vadis?

Authors:  W Kurt Roth
Journal:  Transfus Med Hemother       Date:  2010-05-25       Impact factor: 3.747

Review 4.  Current testing strategies for hepatitis C virus infection in blood donors and the way forward.

Authors:  Neelam Marwaha; Suchet Sachdev
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences.

Authors:  Peter Hellstern
Journal:  Transfus Med Hemother       Date:  2008-03-17       Impact factor: 3.747

6.  10 Autologous Hemotherapy.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

7.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

8.  Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection.

Authors:  Syria Laperche; Nadine Le Marrec; Annie Girault; Françoise Bouchardeau; Annabelle Servant-Delmas; Michèle Maniez-Montreuil; Pierre Gallian; Thierry Levayer; Pascal Morel; Nicole Simon
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

9.  Three-dimensional array-based group testing algorithms.

Authors:  Hae-Young Kim; Michael G Hudgens
Journal:  Biometrics       Date:  2008-11-13       Impact factor: 2.571

10.  Blood screening for influenza.

Authors:  Michael Kai Hourfar; Anna Themann; Markus Eickmann; Pilaipan Puthavathana; Thomas Laue; Erhard Seifried; Michael Schmidt
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.